For CTLA4, Buchbinder and Desai propose in the article that CTLA4 is a negative regulator of T cell immune function and participates in all aspects of immunotherapy for melanoma, non-small-cell lung cancer, and other cancers [27]. This evidence concerns the gene CTLA4 and melanoma.